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Minactivin Expression in Human Monocyte and Macrophage Populations
Blood, Vol 66, No 2 (August). 1985: pp 333-337 333
By Ross W. Stephens, Jeffrey P. Golder, David R.H. Fayle, David A. Hume, Andrew J. Hapel, William Allan,
Carol J. Fordham, and William F. Doe
Adherent monolayer cultures of human blood monocytes,
penitoneal macrophages. bone marrow macrophages, and
colonic mucosa macrophages were examined for their
ability to produce and secrete minactivin, a specific macti-
vator of urokinase-type plasminogen activator. All except
colonic mucosa macrophages produced and secreted
appreciable amounts of minactivin. but only blood mono-
cytes were stimulated by muramyl dipeptide (adjuvant
peptide) to increase production. The minactivin from each
T HE ABILITY OF mononuclear phagocytes to respond
to various stimuli largely depends on their maturity,
and it has been proposed that phenotypic expression of
functions during differentiation is the basis for the functional
heterogeneity of macrophages.’ An example of this is the
induction of tumonicidal activity in murine macrophages in
response to bymphokine. The ability to respond in this way to
lymphokine is only maintained for a short three- to four-day
interval after their migration from the bloodstream into the
tissues.2
We recently have characterized3 a human blood monocyte
product whose production and secretion in vitro is elevated
and sustained after activation by lymphokine, bacterial
lipopolysaccharide, or adjuvant peptide (muramyl dipep-
tide).4 This product, which we have named minactivin, is a
specific inactivator of urokinase-type plasminogen activa-
tors,3 and we have proposed that it has a role in regulating
extracellular proteolysis during tissue remodeling or inva-
sion. It was of interest to determine how expression of this
product may be related to differentiation and particularly
whether it could be expressed by mature tissue macro-
phages.
MATERIALS AND METHODS
Monocyte Preparations
Human blood monocytes. Human mononuclear leukocytes were
isolated on Ficoll-Paque (Pharmacia Fine Chemicals, Sydney, Aus-
tralia) gradients from buffy coats provided by the Red Cross Blood
Transfusion Service of the Woden Valley Hospital. After four
washes in phosphate-buffered saline (Pi/NaCI) at 4 #{176}Cto remove
contaminating platelets, the cell pellet was resuspended in RPMI
1640 (GIBCO, Grand Island, NY) containing 60 U/mL gentami-
cm. Purified monocyte monolayers were obtained by plating I0
mononuclear cells in RPMI 1640 with 10% AB serum into 30-mm
wells (Linbro multiwell plates, Flow Labs, McLean, Va; catalog No.
7605805) that had been precoated for 30 minutes with 2 mL of
human AB serum. Monocytes were allowed to adhere for 60 minutes
at 37 #{176}Cin an atmosphere 5% CO2 in air. Nonadherent cells were
then removed by washing monolayers six times with RPM! 1640
prewarmed at 37 #{176}C.
Peritoneal macrophages. Two-liter lots of diabysate fluid from
patients undergoing routine penitoneal dialysis for chronic renal
failure were centrifuged at 300 g for ten minutes at 20 #{176}C.The cell
pellet was resuspended in 50 mL of RPMI 1640 and recentnifuged
for ten minutes at 200 g at 20 #{176}C.The cells were then resuspended in
RPMI 1640 to a final concentration of approximately 2 x 106/mL,
and 6-mL aliquots of the peritoneal cell suspension were underlayed
with 3 mL of Ficoll-Paque and centrifuged for 20 minutes at 400 g at
of these populations could be shown to preferentially
inhibit urokinase-type plasminogen activator and not tryp-
sin. plasmin. or ‘tissue’-type plasminogen activator
(HPA66). A plasminogen-activating enzyme present in
monocyte cultures appeared unaffected by the presence of
minactivin and could be shown to be regulated indepen-
dently by dexamethasone.
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20 #{176}C.The cells were resuspended to a concentration of I x l0 cells
per milliliter in RPMI 1640 containing 10% human AB serum, and
macrophage monolayers were prepared by adherence to plastic
culture trays as described previously for monocytes.
Bone marrow-derived macrophages. Fresh pieces of human
ileac crest and rib marrow were obtained during orthopedic proce-
dunes and dispersed in RPMI 1640 media containing 10% giant cell
tumor (GCT) culture supernatant (GIBCO-Biocult, Grand Island,
NY) and 10% fetal bovine serum. This primary culture was main-
tamed for seven days on gelatin-coated flasks.5 After this period,
monocyte/macrophages were purified by adherence to culture
dishes prepared as for blood monocytes and the secondary adherent
culture used for minactivin measurements. The cells obtained were
greater than 90% positive for nonspecific esterase. Details of the
method are published elsewhere.6
Colonic mucosa macrophages. These cells were obtained from
resected colons by enzymatic disaggregation of the colonic mucosa
according to the method of Golden and Doe.’ They were grown as
adherent monolayers in RPMI 1640 as for monocytes.
Monocyte and Macrophage Cell Culture
Monocyte or macrophage monolayers were cultured in RPMI
1640 media containing 1% human serum albumin (Commonwealth
Serum Laboratories, Melbourne, Australia). Limulus amebocyte
lysate assays of this culture media showed that the endotoxin level
was less than I ng/mL. Cultures of cells from sources (a) through
(d) above were kept as close as possible to a density of 3 x 106 cells
per milliliter of media.
The following agents were used in cell culture experiments: (a)
muramyl dipeptide (N-acetyl-muramoyl-L-alanyl-D-isoglutamine,
Peninsula Laboratories, San Carlos, Calif), at 5 zg/mL); (b)
Salmonella minnesota R595 cell wall lipopolysacchanide.8 This was
prepared by sonication of the water-insoluble extract in 0.1%
triethylamine followed by extensive dialysis against Pi/NaCb. The
final concentration in cultures was 0.1 ig/mL. Dexamethasone
(Sigma Chemical Co. St Louis) was used at a final concentration of
0.1 zmol/L.
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Fig 1 . Dependence of blood monocyte supernatant minactivin
activity on cell number in culture. Supernatants from 24-hour
cultures with cell numbers shown were assayed undiluted (A-A)
and diluted 1:5 (U-U). 1:10 (-), or 1:20 (v-v). Points
represent averages of duplicate assays.
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Morphology and Cytochemistry
For phase-contrast microscopy, adherent monocyte on macno-
phage monolayens were washed twice and fixed in I .5% glutaralde-
hyde in 0.1 mol/L cacodylate buffer (pH 7.4) for at least 30 minutes
at room temperature9 and examined.
Cytocentnifuge preparations were prepared in a Shandon South-
cnn centrifuge. Briefly, 0.2-mL aliquots containing 50,000 cells in
10% fetal bovine serum were spun for three minutes at 500 rpm. The
preparation was then dried rapidly with a hair dryer, and the
preparations stained with May-Grunwald Giemsa.
The presence of nonspecific estenase was assayed using a-naph-
thyl acetate as
Phagocytic activity was assayed by incubating adherent mono-
layers or cell suspensions in RPMI 1640 containing 10% human AB
serum and I . I zm latex beads (Sigma) at a concentration of 100
beads per cell for 60 minutes at 37 #{176}C.Noningested beads were
removed by washing monolayers or cell suspensions, I 50 g for ten
minutes at 20 #{176}C,three times with RPMI 1640. Cells ingesting two
on more latex beads were judged to be phagocytic.
Colorimetric Assays of Minactivin and Plasminogen
Activator
Minactivin produced in cultures was quantified by the inhibition
produced in colonimetnic assays of human urokinase reference
standard (Calbiochem, Behning Corp. La Jolla, Califl. Interference
by endogenous plasminogen activator was prevented by the ionic
strength ofculture media. When it was required to measure endoge-
nous plasminogen activator, the preparation was dialyzed against 50
mmol/L glycine, pH 7.8, which allowed direct assay despite the
minactivin still present.’2 The assay method for urokinase and for
endogenous plasminogen activator was based on the coupled assay of
Coleman and  For assay of minactivin in cell culture
supernatant or 0.5% Triton lysate, 20 L of the sample was first
preincubated with urokinase (4 milli-Ploug unit [mPUJ in 20 L) for
90 minutes at 23 #{176}C,and then affinity-purified’4 human plasmin-
ogen (4 g in 20 ML) was added and the mixture incubated for 45
minutes at 37 #{176}C.The assay buffer contained 50 mmol/L glycine,
pH 7.8, 0.1% Triton X-l00 (Sigma Chemical Co. St Louis), and
0. 1% gelatin. The plasmin produced was then assayed by the
addition of the thioesterase substrate (Z-lysine-thiobenzyl ester,
Peninsula Laboratories, San Carbos, Calif) and color agent (1 mL)’3
and further incubated for 30 minutes at 37 #{176}C.The final color
development was terminated by the addition of Trasybol (Bayer
Australia Ltd. Botany) ( I 6 g in 20 ML) and the absorbance read at
412 nm. Checks were made to verify that inhibition was at the level
of plasminogen activation and not simply inhibition of plasmin, by
direct addition of the minactivin source to the assay of preformed
plasmin.
Radial Diffusion Assaysfor Specificity Studies
Fibninogen (Sigma, type X), human plasminogen, and thrombin
(Sigma, grade 1 ) were cast in a I .25% agarose (Sea Plaque, FMC
Corp. Rockland, Me) gel matrix 1.2 mm thick. After clotting at
37 #{176}C,the gel was hardened at 4 #{176}C,and 3-mm wells were cut for the
application of protease/minactivin mixtures (5 iL).
The following proteases were used to determine the specificity of
the supposed minactivin from the different cell populations: plasmin
(300 ng), trypsin (50 ng), human urokinase (25 mPU), and culture
supernatant from human melanoma (undiluted). Each of these
enzymes were preincubated for 90 minutes at 23 #{176}Cwith cell culture
supernatant or lysate (total volume 10 iL). The gels were incubated
in a humidified box for 20 hours at 37 #{176}C,and the lysis produced was
enhanced by extensive washing in saline, followed by staining with
amido black.
RESULTS
Macrophage Populations and Minactivin Production
Human blood monocytes. Adherent monolayers were
shown to be greater than 85% monocytes by several criteria.
Polychromatic staining of the monolayer cells showed 94% ±
6% of the cells to be monocytes having a large round or
indented nucleus with basophilic cytoplasm. Staining for the
cytoplasmic enzyme nonspecific esterase showed monolayers
to be 85% ± 2% positive for this monocyte marker. Ninety-
one percent of the adherent cells phagocytosed latex beads,
confirming that the adherent cell population that showed the
morphological and histochemical appearances of mononu-
clear phagocytes also exhibited this characteristic functional
property.
During in vitro culture, monocytes underwent pronounced
changes in cell size and morphology. Cytocentrifuge prepa-
rations of cultured monocytes showed that monocytes con-
tinued to increase in size throughout the culture period, and
by the end of seven days, many cells had more than doubled
in apparent size. Occasional binucleated cells were also seen.
As monocytes increased in size, their cytoplasm became
heavily vacuobated, and cytoplasmic granules also became
evident. Further culture resulted in increased formation of
multinucleated giant cells.
We have shown previously that serum-free conditioned
media from 24-hour cultures of human peripheral blood
monocytes contains a specific inactivator of human uroki-
nase-type plasminogen activators (Fig I), which we have
characterized and named minactivin.3 Minactivin was shown
to be a product of washed, adherent monocytes and was not
produced by cultures of the nonadherent mononuclear cells.
Activation of monocytes in vitro by muramyl dipeptide or
bacterial lipopolysaccharide led to sustained production and
secretion of minactivin (Fig 2A and B).
Human periloneal macrophages. High yields of mono-
nuclear cells were obtained from Ficoll-Paque gradients of
penitoneal washings. Forty-seven percent of the cells were
macrophages as judged by morphological criteria. Cytocen-
trifuge preparations of the mononuclear cell fraction showed
that the macrophage population was heterogeneous and
included large mature cells with abundant cytoplasm and
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Fig 4. Production and secretion of minactivin by human bone
marrow macrophages in secondary culture. Conditions as for Fig
3.
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phage lysate minactivin levels remained high during the
0
DAYS IN CULTURE
Fig 2. Production of minactivin by blood monocyte cultures.
Adherent monocytes were grown in control media (A-A). with
lipopolysaccharide (0.1 jog/mL) (-S). or with muramyl dipep-
tide (10 ug/mL) (-U). (A) Culture supernatants were har-
vested. assayed with urokinase. and replaced with fresh media
every 24 hours. (B) Content of minactivin in cell lysates. Points
are averages of duplicate assays.
occasionally two nuclei, as well as smaller cells more charac-
teristic of monocytes, with indented nuclei and a higher
nucleus-cytoplasm ratio.
Peritoneal macrophages were further purified by adher-
ence to plastic culture trays. After removal of the nonadher-
ent cell layer, viable peritoneal macrophages could be main-
tamed in culture for up to three weeks, provided that the
culture media was changed every two to three days. Perito-
neal monolayers were routinely greater than 87% macro-
phages, as determined by nonspecific esterase staining, and
produced high specific activities of the macrophage marker
enzymes N-acetyl /3-D glucosaminidase, acid phosphatase,
and fl-glucuronidase, thus confirming their purity and viabil-
ity.’t
Although lysates of freshly isolated blood monocytes did
not contain minactivin (see Fig 2B), all the lysates of freshly
isolated adherent peritoneal macrophages studied contained
significant levels of minactivin (approximately 30% inhibi-
tion), which subsequently increased during culture (Fig 3).
High levels of production of minactivin were also reflected in
the output of secreted minactivin found in culture superna-
tants. Unlike control monocyte cultures, peritoneal macro-
DAYS IN CULTURE
Fig 3. Production and secretion of minactivin by human pen-
toneal macrophage culture. Adherent macrophages were grown in
control media (A-A) or with muramyl dipeptide (10 jag/mL)
(-U). The lower two curves represent lysates and the upper
two curves, supernatants. Points are averages of duplicate
assays.
three-day culture period. Moreover, addition of muramyl
dipeptide to peritoneal macrophage cultures did not further
increase minactivin activities in either the lysates or the
supernatants (Fig 3).
Bone marrow-derived macrophages. Bone marrow ma-
crophages were obtained as the adherent cells after seven
days of GCT (giant cell tumor culture supernatant) stimu-
bated growth of primary marrow cultures. In this population,
90% of the cells phagocytosed opsonized zymosan. Because
these cells could only be studied as secondary cultures after
4 the seven-day primary culture of the tissue, their initial
minactivin production and secretion could not be compared
directly with freshly isolated blood monocytes or peritoneal
macrophages.
Not unexpectedly, after primary culture for seven days,
the lysates of adherent bone marrow macrophages obtained
during secondary culture showed high activities of minac-
tivin, which declined regardless of the presence or absence of
muramyl dipeptide (Fig 4).
The secondary cultures of bone marrow cells also secreted
high activities of minactivin into supernatants (Fig 4), but as
with lysates, this level was not affected by muramyl dipep-
tide.
Colonic mucosal macrophages. Macrophages isolated
from enzymicably disaggregated mucosa of resected colon
were greater than 85% nonspecific esterase positive, phago-
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Table 1 . Production of Minactivin by Human Blood Monocytes
Before and After Incubation With Colon Disaggregation
Supernatant Containing DNase and Collagenase
Enzyme-Treated
Control Monocytes Monocytes
Lysate 90% 100%
Supernatant 67% 72%
The results are expressed as percentage of inhibition of urokinase
assay by monocyte supernatant.
cytosed sheep red blood cells, and, as shown previously,7
produce the constitutive macrophage marker enzyme lyso-
zyme. These cells had only limited ability to produce minac-
tivin in culture, however, and the levels were insignificant
compared with those from the three sources above (mean
value of 4% inhibition for 24-hour supernatants in four
experiments). These low levels were not increased when S.
minnesota lipopolysacchanide (0.1 g/mL) was added to
cultures.
To determine whether this lack of responsiveness of intes-
tinal macrophages could be attributed to the prolonged
exposure to the degradative enzymes (coblagenase and
DNase) used in their isolation, some normal human blood
monocytes were subjected to several hours incubation in the
supernatant medium from an intestinal macrophage prepa-
ration. The enzyme-treated blood monocytes retained their
ability to produce and secrete minactivin in subsequent
culture (see Table I).
Specificity ofthe Products From Cell Cultures
The specificity of the supposed minactivin product from
the cells of the different tissue compartments was compared
with that of monocyte minactivin, which we have previously
shown3 to have a high specificity for human urokinase-type
plasminogen activators. A fibrin radial diffusion assay was
used to test for inhibition of a selection of proteases and
activators, including plasmin, trypsin, HPA66 (“tissue-type”
activator from human melanoma culture supernatant), and
human urokinase (containing HPA52 and HPA36).
Culture supernatants from penitoneal macrophages and
blood monocytes showed specific inhibition of urokinase
activity (Fig 5) but did not inhibit the activities of plasmin,
trypsin, or HPA66.
Triton lysates of peritoneal macrophages, blood mono-
cytes, and bone marrow macrophages all produced inhibition
of urokinase, without inhibition of plasmin or trypsin.
Lysates of blood monocytes and peritoneal macrophages also
showed some weak inhibition of HPA66 (see Fig 5).
Independence of Minactivin and Plasminogen Activator
Production
By making use of the salt sensitivity of the endogenous
plasminogen activator,’2 minactivin and plasminogen activa-
tor could be assayed independently in culture supernatants
and in Triton lysates from blood monocytes, peritoneal
macrophages, and bone marrow. Their simultaneous occur-
rence was inconsistent with minactivin serving as a direct
regulator of plasminogen activator from cells of the macro-
phage lineage.’2 Further evidence to support this view was
obtained when blood monocyte cultures were treated with
dexamethasone (I0 mol/L). While minactivin activities in
dialyzed culture supernatants and lysates did not change
significantly (Fig 6A), plasminogen activator activity was
abolished (see Fig 6B), as earlier reported’6 for human
neutrophils.
DISCUSSION
The results extend our previous findings on the human
monocyte product, minactivin, which we have characterized
from normal human blood monocytes.3 Minactivin is able to
inactivate specifically human urokinase-type plasminogen
activators and may have significant actions in regulating
extracellular proteolysis during physiologic or pathologic
events of tissue remodeling and invasion.
Human penitoneal macrophages were found to contain
minactivin when freshly isolated and to go on producing and
secreting it in vitro in appreciable quantities. This cell
population appeared from its morphology to consist largely
of newly recruited monocytes, indicating that the in vivo
stimulus of mild inflammation induced by repeated dialysis
was sufficient to recruit blood monocytes into the penitoneum
and activate them to produce minactivin within the perito-
Fig 5. Radial diffusion fibnin gel assays of
protease inhibition after preincubation with
monocyte/ macrophage minactivin for 90
minutes at 23 ‘C. Row A. human melanoma
cell line supernatant containing HPA66; row
B. urokinase containing HPA52 and HPA36;
row C. trypsin; and row D. plasmin. Columns
1 and 2 included supernatants from cultures
of human penitoneal macrophages and blood
monocytes. respectively. while columns 4
through 6 included lysates of bone marrow
macnophages, penitoneal macrophages. and
blood monocytes. respectively. Columns 3
and 7 represent controls containing culture
media and lysis buffer. respectively. The gel
assay itself was incubated for 20 hours at
37 ‘C.
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Fig 6. (A) Production and secretion of minactivin by blood
monocyte cultures. Control lysate. A-A; control supernatant.
#{149}----#{149};with dexamethasone (10 mol/L); lysate. -B; superna-
tant, #{149}----. Points are averages for duplicates. (B) Production
and secretion of plasmmnogen activator by the same blood mono-
cyte cultures. Symbols for lysates and dialyzed culture superna-
tants for control and dexamethasone-treated cultures are as for
(A).
neal cavity. The peritoneal macrophages appeared to be
unresponsive to further activation, since muramyl dipeptide
did not increase minactivin production or secretion in vitro.
Bone marrow-derived macrophages were also able to
produce appreciable levels of minactivin, although the cells
obtained after seven-day primary culture were not responsive
to muramyl dipeptide. Mature tissue macrophages obtained
from human cobonic mucosa appeared incapable of produc-
ing minactivin in vitro.
Putting these results together, blood monocytes can be
seen to be at the optimal stage of development for potential
secretion of minactivin, a potential that is realized when they
are activated with muramyl dipeptide in vitro or actively
recruited to an inflammatory site in vivo, such as the
peritoneal macrophages above. Mature tissue macrophages,
however, isolated from intestinal mucosa contained little or
no minactivin on isolation and could not be stimulated to
produce or secrete it in vitro.
The relationship between minactivin and the other human
monocyte/macrophage product, plasminogen activator, was
also of interest. In these studies and previously reported work
on blood monocytes,’2 it was shown that, under conditions of
low salt, monocyte plasminogen activator can be assayed in
the presence of minactivin, which is inhibitory when the
sample is added to an assay of urokinase. Minactivin, there-
fore, does not appear to function as a direct regulator of
monocyte plasminogen activator. This was also suggested by
experiments with dexamethasone, which indicated that ste-
roid repression of monocyte pbasminogen activator was
mediated by a minactivin-independent mechanism, so that
the synthesis of these two products may be regulated inde-
pendently.
On the basis of these results we propose that minactivin
may be a useful indicator of inflammatory activity in human
tissues and possibly an active participant in the host-v-tumor
reaction.
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